Comparative Effects of Pindolol and Hydrochlorothiazide in Black Hypertensive Patients

Moser, Marvin; Lunn, John
August 1981
Angiology;Aug1981, Vol. 32 Issue 8, p561
Academic Journal
This article focuses on the comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Most American investigators agree and the Second Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure has again recommended that thiazide diuretics remain the first-step drug of choice for most patients. This may be especially true when treating black hypertensives, several studies have suggested that propranolol, the prototype of β-blockers in the United States is relatively ineffective in these patients. Pindolol has an intermediate duration of action similar to that of metoprolol. It has a partial agonist activity, that is, in addition to blocking β sympathetic activity, it has a partial stimulating effect, bronchial constriction and a decrease in cardiac output may be less marked following its use. Renin levels are not uniformly lowered following the use of pindolol, especially in acute studies, chronic use appears to result in a decrease in renin levels.


Related Articles

  • Using Plasma Renin (PRA) Testing to Design Follow-Up Drug Treatment Strategies in Hypertensive Patients Already Taking Antirenin System Drugs. Sealey, Jean E.; Laragh, John H. // American Journal of Hypertension;Sep2009, Vol. 22 Issue 9, p950 

    The article presents a commentary on the study about using plasma renin (PRA) testing to design drug treatment strategies in hypertensive patients. According to the authors, the information provided by the test can be used to determine whether the patient is more likely to respond to a...

  • Aliskiren. Siragy, Helmy M.; Kar, Santwana; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Oct2007, Vol. 6 Issue 10, p779 

    Aliskiren (Tekturna; Speedel/Novartis) is the first in a new class of drugs that inhibit the protease renin, which has a key role in the regulation of blood pressure. It was approved by the US FDA for the treatment of hypertension in March 2007, and approved in Europe in August 2007 (where it...

  • New molecular entity.  // Formulary;Feb2008, Vol. 43 Issue 2, p39 

    The article discusses the approval of Nebivolol, a beta-adrenergic receptor blocker for the treatment of hypertension. The approval was given on December 17, 2007 as a monotherapy or in combination with other antihypertensive agents. The drug's efficacy was assessed and determined to...

  • BP management -- joined Up guidance at last. Mead, Mike // Update;Jul2006, Vol. 73 Issue 1, p5 

    The article focuses on the updated guidelines on hypertension provided by National Institute for Clinical Excellence (NICE) in Great Britain. The update would replace the recommendations on pharmacological interventions for blood pressure. The new NICE guideline recommends an ACD approach which...

  • BLOWING A GASKET. Kluger, Jeffrey; Adams, Missy; August, Melissa; Baughn, Alice Jackson; Bowers, Paige; Whitaker, Leslie // Time;12/6/2004, Vol. 164 Issue 23, p72 

    Presents advice on how adults with high blood pressure can lower their health risks and improve their quality of life. Consideration of how most patients do not do enough to address symptoms of prehypertension; Growth of the number of heart attacks and blood-pressure problems among younger...

  • Rethink on β-blocker use. Finch, Rob // Pulse;12/20/2004, Vol. 64 Issue 50, p1 

    The article reports that beta-blockers are set to lose their status as a mainstream treatment for hypertension after two landmark trials threw their use into serious doubt. The national hypertension treatment guidelines produced by the British Hypertension Society and National Institute of...

  • FOCUS ON HYPERTENSION.  // Saturday Evening Post;Jul/Aug2006, Vol. 278 Issue 4, p62 

    This article presents various classes of medicines to control blood pressure. Diuretics are considered first-line therapy for hypertension, help the kidneys remove excess fluids and sodium from the body. Beta blockers can help block key chemicals that make the heart beat faster so the heart...

  • Hypertension meeting highlights new theories. Pfeiffer, Naomi // Drug Topics;7/24/2006, Vol. 150 Issue 14, p18 

    The article examines the effectiveness of aliskerin drug for treating mild to moderate hypertension. Aliskerin is the first in a new class of direct renin inhibitors to provide blood pressure control with or without a diuretic. The drug counteracts the tendency of hypertensives to have early...

  • Drug treatment of elevated blood pressure. Nelson, Mark // Australian Prescriber;Aug2010, Vol. 33 Issue 4, p108 

    The decision on when to start drugs for the treatment of elevated blood pressure should be determined by an individual's absolute risk of having an adverse cardiovascular event. The choice of drug depends on its safety and effectiveness and its indications and contraindications for individual...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics